Analyst Stock Ratings Upgrades

Analyst upgrades are typically bullish for a stock. When there is a stock upgrade, the analysts who rate the stock feel better about the company's future and typically either recommend someone holds or buys the stock. Updated 11/20/2024

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating Upgrade News

Deere Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Amazon Remains 'Best Idea' In E-Commerce This Holiday Season, JPMorgan Analyst Says

JPMorgan analyst Doug Anmuth sees strong online sales growth this holiday season and points to Amazon as the firm's "Best Idea" for capturing the momentum.

Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $13 price target.

Chardan Capital Maintains Buy on Metagenomi, Maintains $15 Price Target

Chardan Capital analyst Geulah Livshits maintains Metagenomi (NASDAQ:MGX) with a Buy and maintains $15 price target.

UBS Upgrades Logitech International to Neutral

UBS analyst Joern Iffert upgrades Logitech International (NASDAQ:LOGI) from Sell to Neutral.

Citigroup Maintains Buy on Live Nation Entertainment, Raises Price Target to $163

Citigroup analyst Jason Bazinet maintains Live Nation Entertainment (NYSE:LYV) with a Buy and raises the price target from $130 to $163.

Macquarie Downgrades NIO to Neutral, Lowers Price Target to $4.8

Macquarie analyst Eugene Hsiao downgrades NIO (NYSE:NIO) from Outperform to Neutral and lowers the price target from $6.6 to $4.8.

Barclays Maintains Overweight on Wix.com, Raises Price Target to $236

Barclays analyst Trevor Young maintains Wix.com (NASDAQ:WIX) with a Overweight and raises the price target from $184 to $236.

CIBC Maintains Neutral on TC Energy, Raises Price Target to C$68

CIBC analyst Robert Catellier maintains TC Energy (TSX:TRP) with a Neutral and raises the price target from C$67 to C$68.

Brookline Capital Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $38

Brookline Capital analyst Kumaraguru Raja initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $38.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook